Intestinal brush border transport mechanism of 5-fluorouracil in rats

被引:0
|
作者
Yuasa, H
Matsuhisa, E
Watanabe, J
机构
关键词
intestinal transport; 5-fluorouracil; pyrimidine; brush border membrane vesicle; everted sac; rat;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The intestinal transport mechanism of 5-fluorouracil (5-FU) was investigated in the intestinal everted sacs and brush border membrane vesicles (BBMVs) of rats. In the everted sacs, the initial uptake of 5-FU was apparently Na+-dependent, in terms of the inhibition of the uptake by replacing the Na+ in the medium with K+, and also concentration-dependent in the presence of Na+, with a maximum transport rate of 0.74 +/- 0.24 nmol/min/cm and a Michaelis constant of 0.025 +/- 0.018 mM. Passive transport was also significant, with a membrane permeability clearance of 5.9 +/- 0.6 mu l/min/cm. The uptake of 5-FU was inhibited by pyrimidines (uracil and thymine) and 2, 4-dinitrophenol (DNP), a metabolic inhibitor, but not by purines (adenine and guanine), pyrimidine nucleosides (thymidine and uridine), L-alanine or D-glucose. These results suggest the involvement of carrier-mediated transport specific to pyrimidines in intestinal 5-FU transport, and this appeared to satisfy the criteria of Na+-dependent secondary active transport. However, in BBMVs, 5-FU uptake was independent of Na+, minimally dependent on concentration and not inhibited by thymine, though slightly inhibited by uracil. 5-FU uptake was also independent of pH, outward HCO3- gradient and valinomycin-induced K+ diffusion potential. Thus, the carrier-mediated transport of 5-FU, or presumably pyrimidines, may require some other factors, which are yet to be identified, in addition to Na+. Alternatively, Na+ may not be prerequisite, and something else may be required in the absence of K+, as suggested from an additional result in everted sacs that the replacement of NaCl in the medium with mannitol failed to inhibit 5-FU uptake.
引用
收藏
页码:94 / 99
页数:6
相关论文
共 50 条
  • [41] Niosomal delivery of 5-fluorouracil
    Namdeo, A
    Jain, NK
    JOURNAL OF MICROENCAPSULATION, 1999, 16 (06) : 731 - 740
  • [42] 5-Fluorouracil and dihydropyrimidine dehydrogenase
    Tetsuro Kubota
    International Journal of Clinical Oncology, 2003, 8 (3) : 127 - 131
  • [43] How 5-fluorouracil acts
    Wawrocka-Pawlak, Marlena
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2005, 9 (10): : 414 - 423
  • [44] Effect of early preoperative 5-fluorouracil on the integrity of colonic anastomoses in rats
    Leyla Ozel
    M Sefa Ozel
    Ahmet Burak Toros
    Melih Kara
    Kemal Sirri Ozkan
    Gurkan Tellioglu
    Osman Krand
    Meral Koyuturk
    Ibrahim Berber
    World Journal of Gastroenterology, 2009, 15 (33) : 4156 - 4162
  • [45] Autoregulation of 5-fluorouracil metabolism
    McLeod, HL
    Sludden, J
    Hardy, SC
    Lock, RE
    Hawksworth, GM
    Cassidy, J
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (10) : 1623 - 1627
  • [46] An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug
    Ghoshal, K
    Jacob, ST
    BIOCHEMICAL PHARMACOLOGY, 1997, 53 (11) : 1569 - 1575
  • [47] Pharmacology of Perioperative 5-Fluorouracil
    Van der Speeten, K.
    Stuart, O. A.
    Mahteme, H.
    Sugarbaker, Paul H.
    JOURNAL OF SURGICAL ONCOLOGY, 2010, 102 (07) : 730 - 735
  • [48] Polymeric prodrugs of 5-fluorouracil
    Nichifor, M
    Schacht, EH
    Seymour, LW
    JOURNAL OF CONTROLLED RELEASE, 1997, 48 (2-3) : 165 - 178
  • [49] 5-fluorouracil and cardiotoxicity: a review
    Sara, Jaskanwal D.
    Kaur, Jasvinder
    Khodadadi, Ryan
    Rehman, Muneeb
    Lobo, Ronstan
    Chakrabarti, Sakti
    Herrmann, Joerg
    Lerman, Amir
    Grothey, Axel
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [50] Rechallenge with 5-fluorouracil in a patient who developed encephalopathy caused by 5-fluorouracil for colon cancer
    Takeshi Yamada
    Hayato Kan
    Satoshi Matsumoto
    Michihiro Koizumi
    Seiichi Shinji
    Akihisa Matsuda
    Aya Yamagishi
    Yasuyuki Yokoyama
    Goro Takahashi
    Takuma Iwai
    Eiji Uchida
    International Cancer Conference Journal, 2016, 5 (3) : 131 - 135